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BACKGROUND: Despite improvements in management, infective 
endocarditis remains associated with high mortality and morbidity. We 
describe temporal changes in the incidence, microbiology, and outcomes 
of infective endocarditis and the effect of changes in national antibiotic 
prophylaxis guidelines on incident infective endocarditis.
METHODS: Using a Scotland-wide, individual-level linkage approach, all 
patients hospitalized with infective endocarditis from 1990 to 2014 were 
identified and linked to national microbiology, prescribing, and morbidity and 
mortality datasets. Linked data were used to evaluate trends in the crude 
and age- and sex-adjusted incidence and outcomes of infective endocarditis 
hospitalizations. From 2008, microbiology data and associated outcomes 
adjusted for patient demographics and comorbidity were also analyzed. An 
interrupted time series analysis was performed to evaluate incidence before 
and after changes to national antibiotic prophylaxis guidelines.
RESULTS: There were 7638 hospitalizations (65±17 years, 51% females) 
with infective endocarditis. The estimated crude hospitalization rate 
increased from 5.3/100 000 (95% CI, 4.8-5.9) to 8.6/100 000 (95% CI, 
8.1–9.1) between 1990 and 1995 but remained stable thereafter. There 
was no change in crude incidence following the 2008 change in antibiotic 
prophylaxis guidelines (relative risk of change 1.06 [95% CI, 0.94–1.20]). 
The incidence rate in patients >80 years of age doubled from 1990 to 
2014 (17.7/100 000 [95% CI, 13.4–23.3] to 37.9/100 000 [95% CI, 
31.5–45.5]). The predicted 1-year age- and comorbidity-adjusted case 
fatality rate for a 65-year-old patient decreased in women (27.3% [95% 
CI, 24.6–30.2] to 23.7% [95% CI, 21.1–26.6]) and men (30.7% [95% 
CI, 27.7–33.8] to 26.8% [95% CI, 24.0–29.7]) from 1990 to 2014. Blood 
culture data were available from 2008 (n=2267/7638, 30%), with positive 
blood cultures recorded in 42% (950/2267). Staphylococcus (403/950, 
42.4%) and streptococcus (337/950, 35.5%) species were most common. 
Staphylococcus aureus and enterococcus had the highest 1-year mortality 
(adjusted odds ratio 4.34 [95% CI, 3.12–6.05] and 3.41 [95% CI, 2.04–
5.70], respectively).
CONCLUSIONS: Despite changes in antibiotic prophylaxis guidelines, the 
crude incidence of infective endocarditis has remained stable. However, 
the incidence rate has doubled in the elderly. Positive blood cultures were 
observed in less than half of patients, with Staphylococcus aureus and 
enterococcus bacteremia associated with worse outcomes.
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Despite recent improvements in management, in-fective endocarditis remains associated with high morbidity and mortality.1,2 Over the past few de-
cades, several factors have affected both the incidence 
and outcomes of infective endocarditis. The population 
at risk of infective endocarditis has increased because 
of changes in population demographics, a rise in the 
use of implantable cardiac devices, an increase in the 
number of patients undergoing hemodialysis for end-
stage renal failure, and a greater number of patients 
with congenital heart disease surviving to adulthood.3 
Changes in national guidelines regarding the use of 
antibiotic prophylaxis for prevention of infective endo-
carditis4,5 have also been implicated in the apparent in-
crease in the incidence of infective endocarditis.
Several studies have recently evaluated the changing 
epidemiology of infective endocarditis, predominantly 
incidence,6 before and after guideline recommenda-
tions.4,7–10 Fewer studies have evaluated microbiological 
causes and associated outcomes of endocarditis.11,12 Us-
ing a national linkage approach, we describe the chang-
ing age- and sex-stratified incidence and outcomes of 
infective endocarditis in Scotland over the past 25 years 
and the effect of changes in national guidelines on an-
tibiotic prophylaxis. With the availability of a national 
microbiology surveillance registry from 2008 onward, 
we also describe the microbiology of infective endo-
carditis on the basis of positive blood culture data in a 
subgroup of infective endocarditis hospitalizations be-
tween 2008 and 2014.
METHODS
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. However, 
these individual-level data are available through application 
to the National Health Service Public Health Scotland. Access 
to the data were approved by the National Health Service 
Scotland Public Benefit and Privacy Panel and in accordance 
with the Declaration of Helsinki. As the analysis used rou-
tinely collected and anonymized data, individual patient 
consent was not sought.
Study Design and Data Sources
We conducted a consecutive retrospective individual patient 
linkage study across multiple national databases (Figure I in 
the Data Supplement). In brief, Scottish hospital discharge 
codes were used to identify patients hospitalized with infec-
tive endocarditis. All episodes for patients ≥20 years of age 
admitted between January 1, 1990, and December 31, 2014, 
identified as infective endocarditis were linked to the national 
hospitalization register (Scottish Morbidity Record 01) in 
Scotland. Incident cases of infective endocarditis identified 
from the national hospitalization register between January 1, 
2008, and December 31, 2014, were also linked to positive 
blood culture data derived from individual patients derived 
through linkage with the national microbiology surveil-
lance database (Electronic Communication of Surveillance in 
Scotland; Text I in the Data Supplement).
Participants
Incident episodes of infective endocarditis were identi-
fied from hospital inpatient records using the International 
Classification of Diseases 9 and 10 codes (Text II in the Data 
Supplement). On the basis of our validation exercise, only 
patients with a diagnostic code for endocarditis in the first 
2 positions were included (Text III in the Data Supplement). 
A 5-year look-back period minimized the risk of recurrent 
episodes of infective endocarditis from being misclassified as 
incident cases (Text IV in the Data Supplement).
Covariates
For each patient hospitalization, we extracted age at hos-
pitalization, sex, comorbidity, and socioeconomic status. 
Socioeconomic status was assessed through a national area-
based measure of deprivation, the Scottish Index of Multiple 
Deprivation (SIMD). The SIMD is measured in quintiles with 
the fifth quintile being least deprived. In brief, SIMD identi-
fies small geographical regions (each region related to postal 
[zip] code and corresponding to approximately 750 residents) 
Clinical Perspective
What Is New?
• Several studies have recently evaluated the chang-
ing epidemiology of infective endocarditis before 
and after guideline recommendations. These stud-
ies have predominantly studied the incidence, 
rather than the outcomes or microbiology, of infec-
tive endocarditis.
• Using a national, individual patient-level linkage 
approach, we describe the changing age- and 
sex-stratified incidence and outcomes of infective 
endocarditis in Scotland between 1990 and 2014.
• We further describe temporal changes in patient 
characteristics and microbiology based on posi-
tive blood cultures associated with infective 
endocarditis.
What Are the Clinical Implications?
• The crude incidence rate of infective endocarditis 
hospitalizations increased from 1990 to 1995 but 
has remained relatively static thereafter with both 
short- and long-term adjusted case fatality rates 
showing a steady decrease over the past 25 years.
• The majority of patients with endocarditis in our 
cohort did not have positive blood cultures and in 
those with positive microbiology, staphylococcus 
and enterococcus conferred the highest risk for all-
cause mortality.
• Changes in guidelines regarding antibiotic prophy-
laxis in the United Kingdom have not resulted in 
a significant change in incident cases of infective 
endocarditis.
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of material deprivation based on information derived from 7 
domains (income; employment; health; education, skills and 
training; geographic access to services; crime; and housing).13 
Scores from each domain (which are themselves weighted 
according to their relative importance) are combined into an 
overall score, which allows that area to be ranked. Scores 
and ranks based on SIMD have been used extensively in pub-
lished epidemiological research from Scotland,14,15 including 
guiding primary prevention in Scotland.16 For our study, every 
patient enrolled in our cohort was assigned a SIMD quintile 
on the basis of their individual SIMD rank at the time of their 
index admission.
Patient comorbidities were defined using established 
International Classification of Diseases codes on the basis of 
previous hospitalizations and procedures using a 5-year look-
back period. For every case of infective endocarditis during 
the 25-year period from 1990 until 2014, we extracted the 
following comorbidity data: (history of) myocardial infarc-
tion, cerebrovascular disease, heart failure hospitalization, 
implanted cardiac device, and cardiothoracic surgery (Text II in 
the Data Supplement). From 2009 onward, prescribing data 
were used to provide additional comorbidity classifications on 
the basis of dispensed drugs (Text V in the Data Supplement).
Statistical Analysis
Baseline characteristics of all hospitalizations were summa-
rized by 5 calendar year groups from 1990 to 2014 and 
in single calendar year groups from 2008 onward. Baseline 
characteristics were also summarized by blood culture sta-
tus. Incident hospitalizations were summed by calendar 
year, age, and sex. Midyear population estimates for the 
general population in Scotland, stratified by age and sex, 
were obtained from the National Records of Scotland. For 
people without incident infective endocarditis, person-
time not at risk (attributable to incident infective endo-
carditis events) was also summed by the same stratifying 
variables. Within the levels of these stratifying variables, 
person-time for people with no infective endocarditis was 
obtained by subtracting the infective endocarditis person-
time from the midyear population estimates (Text IV in the 
Data Supplement). Outcomes consisted of mortality, stroke, 
heart failure hospitalization, and valve surgery at 30-days 
and 1-year following the index presentation.
Modeling
Generalized additive models were used to estimate trends 
in incidence and outcomes of infective endocarditis. For 
incidence rates, log-link and Poisson error distribution were 
used with a scaling factor (quasi-Poisson) to allow for over-
dispersion. Incidence rates per year were generated for the 
whole population and stratified by sex and age. For out-
comes, 1-year mortality was the primary outcome and year 
of admission as the primary explanatory variable adjusted 
for age, sex, comorbidity, and deprivation. For both estima-
tion of trends in the incidence rates and outcomes of infec-
tive endocarditis, models were fitted using nonparametric 
smooth terms (penalized thin plate regression splines) for 
the year of admission. For the analysis of the association 
between 30-day and 1-year mortality and microbiology, 
logistic regression models were constructed adjusted for 
age, sex, deprivation, and comorbidity.
An interrupted time series analysis17 was used to eval-
uate the incident rates of infective endocarditis before 
(2001–2007) and after (2008–2014) the introduction of 
new antibiotic prophylaxis guidelines from the National 
Institute of Health and Care Excellence (Text VI in the Data 
Supplement).18 A sensitivity analysis was also performed to 
evaluate the effect of restricting the cohort to the first diag-
nostic coding position. Statistical analysis was performed in 
R, version 3.5.1 (Vienna, Austria).
RESULTS
Across 7513 individual patients, there were 7638 hospi-
talizations (mean age 65±17 years, 51% women) with 
incident infective endocarditis from 1990 to 2014 in 
Scotland (Table 1; Table I in the Data Supplement).
The estimated crude rate of hospitalization increased 
from 5.3 per 100 000 (95% CI, 4.8–5.9) to 8.6 per 
100 000 (95% CI, 8.1–9.1) between 1990 and 1995 
but remained stable thereafter with the incident rate in 
2014 of 8.1 per 100 000 (95% CI, 7.5–8.9) (Figure 1A; 
Table II in the Data Supplement). Similar relative chang-
es were seen in the incidence of infective endocarditis 
in our sensitivity analysis restricting the cohort to the 
first diagnostic code position (Figure II in the Data Sup-
plement). Estimated rates comparing men and women 
also appeared similar up until 2003 but appeared to 
diverge thereafter (Figure III in the Data Supplement; 
Table II in the Data Supplement).
When stratified by age, patients >80 years showed a 
marked increase in the incidence of infective endocardi-
tis rising from 17.7 per 100 000 (95% CI, 13.4–23.3) in 
1990 to 37.9 per 100 000 (95% CI, 31.5–45.5) in 2014 
(Figure 1B; Table III in the Data Supplement). In contrast, 
in the 60- to 79-year age group, the estimated rate was 
11.5 per 100 000 (95% CI, 10.1–13.2) in 1990 peak-
ing at 20.6 per 100 000 (95% CI, 19.2–22.0) in 1996 
before steadily decreasing to 12.6 per 100 000 (95% 
CI, 11.1–14.3) in 2014. In the younger age groups, the 
incident rates of endocarditis appeared relatively un-
changed (Figure 1B; Table III in the Data Supplement). 
There was no change in the incident rate of infective 
endocarditis following implementation of National In-
stitute of Health and Care Excellence guidelines on an-
tibiotic prophylaxis (relative risk of change, 1.06 [95% 
CI, 0.94–1.20], P=0.420; Figure 2).
During the study period, 32% (2426/7638) of pa-
tients admitted to hospital with infective endocarditis 
died within 1 year of admission. Both age and sex in-
fluenced 1-year mortality, adjusted for deprivation and 
comorbidity (Table IV in the Data Supplement). Age-ad-
justed and sex-stratified predicted case fatality rates are 
shown in Figure IV and Table V in the Data Supplement. 
For a 65-year-old female, the predicted risk of 1-year 
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mortality reduced from 27.3% in 1990 (95% CI, 24.6–
30.2) to 23.7% (95% CI, 21.0–26.6) in 2014. Similarly, 
for a 65-year-old male, the risk of 1-year death fell from 
30.7% (95% CI, 27.7–33.8) to 26.8% (95% CI, 24.0–
29.7). History of cerebrovascular disease (adjusted odds 
ratio [OR], 1.28 [95% CI, 1.07–1.49]), heart failure hos-
pitalization (OR, 2.09 [95% CI, 1.96–2.22]), and depri-
vation (OR, 0.92 [95% CI, 0.88–0.95] per unit incre-
ment in rank; rank 1 assigned as being most deprived 
and rank 5 as least deprived) were also associated with 
a higher risk of death at 1 year.
Data on incident cases of infective endocarditis 
were available from 1990 to 2014. However, positive 
blood culture data were also available from 2008 until 
2014. As such, the population with blood culture mi-
crobiology linkage consisted of 30% (2267/7638) of all 
hospitalizations (Table 2). Positive blood cultures were 
recorded in 42% (950/2267) of hospitalizations with 
the majority of the remainder being culture negative 
(defined as individuals in whom blood cultures yielded 
no organism or in whom no cultures were performed).
From our validation exercise, 12.5% of patients with 
a clinical diagnosis of infective endocarditis did not have 
blood cultures taken (Text III in the Data Supplement). At 
a national level, we could link patient level data to positive 
microbiology only using the Electronic Communication of 
Surveillance in Scotland registry. As such, it was neither 
possible to determine what proportion of the remaining 
1317 cases were associated with sterile blood cultures 
nor possible to determine what proportion did not have 
blood cultures performed. However, extrapolating from 
our validation data, where 87.5% of all cases had blood 
cultures performed, we assume that the majority of the 
1317 cases also had blood cultures performed with a sig-
nificant proportion yielding no growth.
Staphylococcus (403/950, 42.4%), streptococcus 
(337/950, 35.5%), and enterococcus (85/950, 8.9%) 
were the most common organisms identified (Figure 
V in the Data Supplement). The majority of staphylo-
cocci were Staphylococcus aureus (301/403, 74.7%). 
Across the years, positive microbiology rate increased 
from 34.7% in 2008 to 45.4% in 2014 (Figure VI in 
the Data Supplement). Several factors were associat-
ed with 30-day and 1-year mortality (Figure VII in the 
Data Supplement and Figure  3, respectively). Com-
pared with patients without positive blood cultures, 
those with Staphylococcus aureus and enterococcus 
were at the highest risk of 1-year mortality (OR, 4.34 
[95% CI, 3.12–6.05] and OR, 3.41 [95% CI, 2.04–
5.70], respectively).
Table 1. Baseline Characteristics and Outcomes in Patients Hospitalized With Infective Endocarditis, Stratified by 5-Year Calendar Groups
Baseline Characteristics
Calendar Years in 5-Year Groups
1990–1994
(n=1379)
1995–1999
(n=1642)
2000–2004
(n=1464)
2005–2009
(n=1537)
2010–2014
(n=1616)
Age, y, mean (SD) 62.10 (17.25) 64.62 (16.34) 65.32 (17.59) 66.01 (16.92) 66.56 (17.96)
Women, n (%) 771 (55.9) 855 (52.1) 775 (52.9) 751 (48.9) 768 (47.5)
Scottish Index of Multiple Deprivation, n (%)
  Rank 1 (most deprived) 402 (29.4) 404 (24.7) 387 (26.6) 369 (24.1) 365 (22.7)
  Rank 2 327 (23.9) 363 (22.2) 351 (24.1) 326 (21.3) 376 (23.4)
  Rank 3 233 (17.1) 310 (19.0) 257 (17.7) 318 (20.7) 319 (19.9)
  Rank 4 223 (16.3) 276 (16.9) 254 (17.5) 273 (17.8) 274 (17.1)
  Rank 5 (least deprived) 181 (13.3) 282 (17.2) 205 (14.1) 248 (16.2) 271 (16.9)
Previous medical conditions and interventions, n (%)
  Myocardial infarction 59 (4.3) 89 (5.4) 60 (4.1) 65 (4.2) 80 (5.0)
  Cerebrovascular disease 68 (4.9) 108 (6.6) 83 (5.7) 82 (5.3) 75 (4.6)
  Heart failure hospitalization 220 (16.0) 315 (19.2) 251 (17.1) 206 (13.4) 173 (10.7)
  Cardiac device 25 (1.8) 45 (2.7) 48 (3.3) 42 (2.7) 48 (3.0)
  Prior cardiac valvular surgery 151 (10.9) 161 (9.8) 136 (9.3) 119 (7.7) 130 (8.0)
Outcomes at 30 days, n (%)
  All-cause death 196 (14.2) 233 (14.2) 231 (15.8) 198 (12.9) 223 (13.8)
  Heart failure hospitalization 41 (3.0) 58 (3.5) 75 (5.1) 84 (5.5) 74 (4.6)
  Subsequent valve surgery 64 (4.6) 77 (4.7) 66 (4.5) 73 (4.7) 86 (5.3)
Outcomes at 1 year, n (%)
  All-cause death 435 (31.5) 515 (31.4) 490 (33.5) 486 (31.6) 500 (30.9)
  Heart failure hospitalization 189 (13.7) 215 (13.1) 177 (12.1) 191 (12.4) 158 (9.8)
  Subsequent valve surgery 141 (10.2) 155 (9.4) 157 (10.7) 179 (11.6) 181 (11.2)
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In our sensitivity analysis restricting the cohort to 
the first diagnostic code position, positive blood cul-
tures were identified in 63% (753/1195) of patients 
(Figure VIII in the Data Supplement). Similar to the 
primary analysis, those with Staphylococcus aureus 
and enterococcus were at the highest risk of 1-year 
mortality (OR, 2.23 [95% CI, 1.47–3.39] and OR, 1.89 
[95% CI, 1.05 – 3.42], respectively), compared with 
patients without positive blood cultures (Figure IX in 
the Data Supplement).
DISCUSSION
In this nationwide population cohort study using in-
dividual patient-level data linkage, we make several 
important observations. First, although the estimated 
overall crude incidence of infective endocarditis has 
remained relatively stable from 1995 onward, when 
stratified by age, there was a 2-fold increase in inci-
dence in the elderly but either decreasing or static rates 
in younger patients. Second, the adjusted case fatality 
rate after endocarditis remains high but has declined 
over the past 25 years. After adjustment for age and 
comorbidity, men had overall higher case fatality rates 
than women. Third, fewer than half of all patients had 
positive blood cultures, with the overall positive blood 
culture rate increasing from 35% in 2008 to slightly 
less than half in 2014. Where a causative organism was 
identified, staphylococcus and streptococcus were the 
most common species. Fourth, compared to patients 
with no positive blood cultures patients with Staphy-
lococcus aureus or enterococcus bacteremia had the 
highest risk of death. Last, and perhaps of most clinical 
relevance, our analysis has shown that the 2008 change 
in antibiotic prophylaxis guidelines in the United King-
dom has not resulted in a significant rise in incident 
cases of infective endocarditis.
Population-based studies in endocarditis remain 
scarce with the majority of epidemiology extrapolated 
from hospital-based cohorts or cross-sectional stud-
ies.19,20 Our dataset included cases of infective endo-
carditis over the past 25 years. Whereas we only had 
positive blood culture data for a fifth of this period, 
evaluating the overall period allowed us to investigate 
long-term trends in incidence of and outcomes after 
hospitalization with infective endocarditis. With the 
Figure 1. Estimated incidence rate per 100 000 in the population (A) and stratified by age groups (B).
Blue circles in A represent the absolute crude rates with the size of the circles proportional to the absolute count. The solid blue line represents the estimated inci-
dent rate from generalized additive modeling using the Poisson distribution. The dashed blue lines represent the corresponding upper and lower 95% CI bounds.
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exception of recent large population-based time-series 
analyses evaluating the temporal incidence of endocar-
ditis in England4,21 and the United States,7,22 the ma-
jority of studies are limited by sample size, consisting 
of <1000 patients.20 All of these studies are further 
limited by incomplete characterization of participant 
demographics and characteristics, including comor-
bidity, case-fatality rates, and microbiology. Using an 
established national linkage approach in Scotland,23,24 
we identified >7000 hospitalizations with a diagnosis 
of infective endocarditis and provide detailed individual 
patient-level information on baseline demographics, 
comorbidity burden, associated microbiology data, and 
subsequent case fatality rates.
As such, there are several strengths to our study. 
First, our approach ensured complete follow-up in those 
patients who remained resident in Scotland during the 
study period. Indeed, similar linkages have already been 
used to deliver randomized clinical trials23,25 and cohort 
studies24 in Scotland. Second, our cohort consisted of 
consecutive patients hospitalized with a diagnostic code 
for infective endocarditis, avoiding selection bias and 
ensuring that our study population was representative. 
Third, unlike previous administrative data assets using 
diagnostic coding data to determine culture status,7,22 
which may not have been restricted to blood stream in-
fections, we have used primary patient-level data from 
Scottish microbiology laboratories to ensure accurate 
recording of positive blood culture status. Fourth, using 
source clinical data, we validated the accuracy of the di-
agnostic coding including code position and microbiol-
ogy data using data from local microbiology laboratory 
information systems (ensuring consistency with the na-
tional microbiology surveillance systems across Scotland).
Three relatively recent guideline updates have 
emerged from the National Institute of Health and 
Care Excellence18 in the United Kingdom, the American 
Heart Association,26 and the European Society of Car-
diology.2 These guidelines have recommended either 
complete or partial cessation of antibiotic prophylaxis 
in patients at moderate or high risk of infective endo-
carditis. Subsequent analyses evaluating the incidence 
of infective endocarditis have shown contrasting re-
sults. In England, a significant reduction in antibiotic 
Figure 2. Plot showing the observed incident rates per 100 000 by year of hospitalization (black dots), in relation to the introduction of national 
antibiotic prophylaxis guidelines.
The shaded gray box indicates introduction of National Institute of Health and Care Excellence antibiotic prophylaxis guidelines. The black line shows the predicted 
incident rate using the model described in Text VI in the Data Supplement, incorporating the change in guidelines from 2008 onward. The overlying red line shows 
the predicted incident rate assuming the counterfactual of no change in antibiotic prophylaxis guidelines in 2008.
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prescriptions and an apparent rise in the incidence of 
endocarditis was observed following the introduction 
of changes to National Institute of Health and Care 
Excellence guidelines.2,4 Similar results were noted in 
a US-based population comparing incidence before 
and after changes to antibiotic prophylaxis guidelines 
in 2007.7 In contrast, 3 studies from the United States 
showed no increase in incidence following changes 
to antibiotic prophylaxis guidelines.8,27,28 These stud-
ies, however, were either limited in terms of cohort 
size8 or evaluated incident rates over a shorter time 
frame following the change in guidelines.27 Further-
more, small but well-characterized populations in the 
United States29 and France10 have also reported static 
incident rates. In our study, the crude incident rate 
of infective endocarditis increased in Scotland from 
1990 until 1995 but remained relatively static there-
after, suggesting that changes to clinical guidelines 
regarding antibiotic prophylaxis were not associated 
with an adverse effect on the incidence of infective 
endocarditis in Scotland.
We observed an important interaction between age 
and rates of endocarditis. The incidence in patients old-
er than 80 years of age increased 2-fold, while remain-
ing static or decreasing in younger populations. This 
striking increase in the elderly is multifactorial and most 
likely reflects changes in the incidence of degenera-
tive valvular heart disease, a rise in the number of pa-
tients surviving with multiple comorbidities, an increase 
in the provision of invasive therapeutic interventions, 
including implantable cardiac devices (pacemakers, 
defibrillators, closure devices, and percutaneous valve 
technology)30 and hemodialysis,31 and more extensive 
investigations32 in frail, elderly patients.
We report important differences in the microbiology 
of patients with infective endocarditis compared with 
many studies in the existing literature. In our study, with 
linkage to a robust national microbiology laboratory 
blood culture dataset, no causative organism was iden-
tified in the majority (57%) of patients. In the published 
literature, culture-negative endocarditis varied from 
15% to 60% across both hospital-based cohorts20,33 
Table 2. Baseline Characteristics and Outcomes in Patients Hospitalized With Infective Endocarditis, by Blood Culture Status and Organism 
Identified
Baseline Characteristics
Culture 
Negative/
No Cultures 
(n=1317)
Staphylococcus 
aureus
(n=301)
Staphylococcus 
(Coagulase 
Negative)
(n=102)
Streptococcus
(n=337)
Enterococcus
(n=85)
Polymicrobial/
Other
(n=125)
Age, y, mean (SD) 69.5 (16.9) 58.92 (19.09) 65.41 (14.95) 63.35 (17.39) 70.28 (13.06) 60.83 (19.22)
Women, n (%) 735 (55.8) 113 (37.5) 40 (39.2) 107 (31.8) 29 (34.1) 53 (42.4)
Scottish Index of Multiple Deprivation, n (%)
  Rank 1 (most deprived) 279 (21.3) 92 (30.7) 21 (20.6) 73 (21.7) 29 (34.1) 33 (26.6)
  Rank 2 320 (24.5) 69 (23.0) 23 (22.5) 47 (14.0) 21 (24.7) 40 (32.3)
  Rank 3 286 (21.9) 54 (18.0) 17 (16.7) 70 (20.8) 13 (15.3) 17 (13.7)
  Rank 4 218 (16.7) 44 (14.7) 23 (22.5) 70 (20.8) 11 (12.9) 20 (16.1)
  Rank 5 (least deprived) 205 (15.7) 41 (13.7) 18 (17.6) 76 (22.6) 11 (12.9) 14 (11.3)
Previous medical conditions and interventions, n (%)
  Myocardial infarction 68 (5.2) 12 (4.0) 8 (7.8) 17 (5.0) <5 5 (4.0)
  Cerebrovascular disease 62 (4.7) 13 (4.3) 7 (6.9) 15 (4.5) 9 (10.6) 6 (4.8)
  Heart failure hospitalization 157 (11.9) 29 (9.6) 14 (13.7) 34 (10.1) 6 (7.1) 18 (14.4)
  Cardiac device 27 (2.1) 12 (4.0) 8 (7.8) <5 <5 6 (4.8)
  Cardiac valve surgery 71 (5.4) 17 (5.6) 27 (26.5) 30 (8.9) 10 (11.8) 16 (12.8)
  Chronic respiratory disease* 195 (19.1) 36 (14.8) 13 (15.5) 58 (20.7) 16 (22.5) 16 (16.2)
  Diabetes mellitus* 133 (13.0) 35 (14.4) 22 (26.2) 30 (10.7) 11 (15.5) 18 (18.2)
Outcomes at 30 days, n (%)
  All-cause death 130 (9.9) 130 (9.9) 71 (23.6) 26 (25.5) 49 (14.5) 12 (14.1)
  Heart failure hospitalization 78 (6.0) 6 (2.0) <5 15 (4.5) <5 7 (5.6)
  Subsequent valve surgery 23 (1.8) 35 (11.6) 5 (4.9) 46 (13.6) 5 (5.9) 7 (5.6)
Outcomes at 1 year, n (%)
  All-cause death 336 (25.5) 133 (44.2) 46 (45.1) 99 (29.4) 43 (50.6) 41 (32.8)
  Heart failure hospitalization 159 (12.1) 18 (6.0) 10 (9.8) 33 (9.8) 6 (7.1) 16 (12.8)
  Subsequent valve surgery 87 (6.6) 54 (17.9) 18 (17.6) 85 (25.2) 9 (10.6) 19 (15.2)
*Based on community prescribing (see Text V in the Data Supplement).
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and population registries that are based primarily on US 
populations.7,22,34 Several reasons might explain our low 
culture-positive rates. First, we defined infective endo-
carditis using diagnostic coding. Although this is more 
sensitive and eliminated selection bias, it is possible that 
the lower rates of culture-positive cases reflect lower 
specificity by including some patients with lower prob-
ability of infective endocarditis. We validated the accu-
racy of the diagnostic coding using an in-depth health 
record review of nearly 400 cases. Restricting the patient 
population to the first 2 diagnostic positions gave an 
overall positive predictive value for definite or probable 
diagnosis of infective endocarditis of 88%. As such, 
case ascertainment bias caused by coding error is unlike-
ly to have made a significant contribution. Second, from 
2009 to 2012, 3 laboratories did not provide complete 
microbiology data for national linkage. These laborato-
ries were small and served <1.5% of the Scottish popu-
lation and would therefore have a negligible effect on 
the rates of positive blood cultures. Third, across most 
hospitalized cohorts of patients with infective endocar-
ditis, cases were identified by the attending clinician.35 A 
high culture-positive rate in these cohorts may therefore 
reflect selection bias toward patients with positive blood 
cultures.11 Across population registry data, the culture-
negative rates were higher7,22 with similar rates to those 
observed in Scotland.34 Fifth, across both population 
registries7,22 and some hospital-based cohorts,36 culture 
status was not restricted to blood cultures but also in-
cluded tissue cultures including valves and serological 
tests, invariably increasing the rates of culture-positive 
diagnosis.36 It is reassuring that, where positive blood 
cultures were obtained in our cohort, streptococcus 
and staphylococcus were the most commonly identified 
pathogens, consistent with the wider literature.37,38 Last, 
we noticed a relative rise of 16% in the proportion of 
patients with culture-positive infective endocarditis from 
2008 to 2014. This observation likely reflects more ju-
dicious timing of administration of antibiotic treatment 
and ensuring blood cultures are taken prior to initiation 
of therapy; clinical practice that has been emphasized in 
recent international guidelines.39
Across the study cohort, crude temporal mortality 
rates at 1-year remained stable, ranging from 27% to 
33%. However, after adjustment, we observed a steady 
reduction in mortality. A recent large US-based study 
showed a similar relationship with decreasing mortality 
over a similar time period22 while others have shown 
little or no change in case fatality.4,40 Positive microbi-
ology was independently associated with poorer out-
comes. Staphylococcus aureus bacteremia was inde-
pendently associated with a 4-fold increased mortality 
rate at 30-days and 1-year. In contrast, the magnitude 
of association for enterococcus bacteremia changed 
from a 2-fold increased risk at 30-days to 3-fold in-
creased risk at 1 year. This observation likely reflects a 
frailer and older population that is more susceptible to 
enterococcus bacteremia41,42 and at higher risk of me-
dium- to long-term mortality.43–45
LIMITATIONS
There are several limitations to our study. First, index cas-
es and comorbidity were defined using administrative 
Figure 3. Forest plot showing odds ratio from logistic regression evaluating the association between all-cause mortality at 1 year and patient demo-
graphics, comorbidity, and microbiology.
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datasets, which are subject to inaccurate coding. How-
ever, we improved coding specificity for infective endo-
carditis using data from our validation work. To ensure 
a reasonable balance between specificity and sensitiv-
ity, we included all hospitalizations with a diagnostic 
code appearing in the first 2 (of 6) positions only. Re-
stricting the population to the first diagnostic position 
markedly reduced the sensitivity for infective endocar-
ditis in previous literature.22 Second, for our validation 
exercise, the diagnosis of infective endocarditis was on 
the basis of a clinician documented diagnosis of infec-
tive endocarditis. Although we acknowledge that the 
Modified Duke Criteria represent the gold standard for 
defining cases of infective endocarditis,2 unfortunately 
the  majority of clinicians did not reference these cri-
teria in clinical notes entered on electronic patient re-
cords. For example, the presence or absence of physical 
examination findings relevant to the minor criteria (eg, 
vascular or immunologic phenomena) were frequently 
not documented. After careful consideration of the 
impact of these missing data, and the potential for in-
troducing significant bias, our research team elected 
to use a more pragmatic approach with true cases of 
infective endocarditis defined as those clinically docu-
mented and treated as infected endocarditis. Third, 
we could not differentiate patients with blood culture-
negative infective endocarditis from those patients in 
whom blood cultures were not performed. From our 
validation work, we suspect that just more than 10% 
of all patients will fall into the latter category. Fourth, 
while we have attempted to address the majority of 
confounders, residual unmeasured confounding may 
have affected the trends observed in case fatality rates 
and the associations evaluating microbiology and risk 
of mortality.
CONCLUSIONS
We report important temporal changes in patients 
with infective endocarditis in the Scottish population 
over the past 25 years. The crude incidence of infec-
tive endocarditis increased from 1990 to 1995 but has 
remained relatively static thereafter. It is of note that 
the incidence has increased 2-fold in the elderly. Both 
short- and long-term adjusted case fatality rates of in-
fective endocarditis have shown a steady decrease over 
the past 25 years. Last, and of most interest, the major-
ity of patients with infective endocarditis in our cohort 
did not have positive blood cultures. In those patients 
with positive microbiology, staphylococcus and entero-
coccus conferred the highest risk of all-cause mortality. 
Our data highlight that infective endocarditis remains a 
lethal condition, especially in the elderly. We also dem-
onstrate the importance of microbiology data for prog-
nostication, not only for in-hospital mortality but also 
for medium-term outcomes. As such, our data further 
support the multidisciplinary integration of cardiology, 
microbiology and infectious disease teams as advo-
cated by international guidelines to optimize diagnosis 
and patient care.2
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